Rajesh Kumar
Stock Analyst at HSBC
(2.45)
# 2,125
Out of 5,182 analysts
33
Total ratings
42.86%
Success rate
4.7%
Average return
Main Sectors:
Stocks Rated by Rajesh Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Downgrades: Reduce | $1,070 → $850 | $874.00 | -2.75% | 4 | Mar 17, 2026 | |
| PFE Pfizer | Maintains: Buy | $29 → $32 | $26.48 | +20.85% | 2 | Mar 17, 2026 | |
| BIIB Biogen | Maintains: Reduce | $143 → $150 | $183.38 | -18.20% | 2 | Mar 17, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $60 | $58.26 | +2.99% | 3 | Mar 17, 2026 | |
| ABBV AbbVie | Upgrades: Buy | $225 → $265 | $197.69 | +34.05% | 5 | Dec 10, 2025 | |
| NVO Novo Nordisk | Downgrades: Hold | n/a | $41.17 | - | 3 | Nov 24, 2025 | |
| IQV IQVIA Holdings | Upgrades: Buy | $195 → $235 | $158.98 | +47.82% | 2 | Oct 9, 2025 | |
| KDP Keurig Dr Pepper | Upgrades: Buy | $36 → $42 | $28.79 | +45.88% | 1 | Apr 25, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $660 → $670 | $470.22 | +42.49% | 3 | Apr 30, 2024 | |
| DHR Danaher | Upgrades: Buy | $250 → $280 | $178.98 | +56.44% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $460 | $366.77 | +25.42% | 2 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $31.62 | -58.89% | 1 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Reduce | $97 | $47.14 | +105.77% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $124 | $102.06 | +21.50% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $123 | $110.03 | +11.79% | 1 | Jul 14, 2023 |
Eli Lilly and Company
Mar 17, 2026
Downgrades: Reduce
Price Target: $1,070 → $850
Current: $874.00
Upside: -2.75%
Pfizer
Mar 17, 2026
Maintains: Buy
Price Target: $29 → $32
Current: $26.48
Upside: +20.85%
Biogen
Mar 17, 2026
Maintains: Reduce
Price Target: $143 → $150
Current: $183.38
Upside: -18.20%
Bristol-Myers Squibb Company
Mar 17, 2026
Maintains: Hold
Price Target: $53 → $60
Current: $58.26
Upside: +2.99%
AbbVie
Dec 10, 2025
Upgrades: Buy
Price Target: $225 → $265
Current: $197.69
Upside: +34.05%
Novo Nordisk
Nov 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $41.17
Upside: -
IQVIA Holdings
Oct 9, 2025
Upgrades: Buy
Price Target: $195 → $235
Current: $158.98
Upside: +47.82%
Keurig Dr Pepper
Apr 25, 2025
Upgrades: Buy
Price Target: $36 → $42
Current: $28.79
Upside: +45.88%
Thermo Fisher Scientific
Apr 30, 2024
Maintains: Buy
Price Target: $660 → $670
Current: $470.22
Upside: +42.49%
Danaher
Apr 17, 2024
Upgrades: Buy
Price Target: $250 → $280
Current: $178.98
Upside: +56.44%
Apr 4, 2024
Upgrades: Hold
Price Target: $460
Current: $366.77
Upside: +25.42%
Dec 18, 2023
Initiates: Buy
Price Target: $13
Current: $31.62
Upside: -58.89%
Jul 14, 2023
Initiates: Reduce
Price Target: $97
Current: $47.14
Upside: +105.77%
Jul 14, 2023
Initiates: Buy
Price Target: $124
Current: $102.06
Upside: +21.50%
Jul 14, 2023
Initiates: Hold
Price Target: $123
Current: $110.03
Upside: +11.79%